DWA
DNTH icon

Dorsey Wright & Associates’s Dianthus Therapeutics DNTH Stock Holding History

Dorsey Wright & Associates’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-40
Closed -$9K – 298
2019
Q2 		$9K Buy
+40
New +$9.89K ﹤0.01% 269

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

Dorsey Wright & Associates's DNTH Position: Q3 2019 in Review

Dorsey Wright & Associates sold out of Dianthus Therapeutics (DNTH) in Q3 2019, closing a stake of 40 shares — an estimated $9K sold.

Dorsey Wright & Associates first reported a position in DNTH in Q2 2019 and held it in 1 quarter. The position peaked at $9K in Q2 2019. 72 funds tracked by Wall St. Rank hold DNTH as of Q3 2019.

  • Dorsey Wright & Associates reported no remaining Dianthus Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Dorsey Wright & Associates sold 40 Dianthus Therapeutics shares in Q3 2019, an estimated $9K.
  • Dorsey Wright & Associates first reported a position in Dianthus Therapeutics in Q2 2019 and held it in 1 quarter.
  • Dorsey Wright & Associates's Dianthus Therapeutics position peaked at $9K in Q2 2019.
  • 72 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2019.

Based on Dorsey Wright & Associates's 13F filing for Q3 2019, filed 31 Oct 2019.